Of the 26 companies that make up the Genome Technology Index, fully half were not public a year ago. At our editorial closing another dozen genome technology IPOs were in the pipeline.
We think an industry this dynamic deserves its own benchmark. So we’ve created one.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
